Lonza Group AG stock (CH0013841017): CDMO heavyweight back in focus after latest trading update

Lonza Group AG remains a key player in the global CDMO market. After its recent trading update and capital markets communication for the 2024 financial year, investors are reassessing growth prospects, margins and pipeline visibility for the Swiss group.

Lonza Group AG has once again moved into the spotlight after publishing its annual reporting and trading update for the 2024 financial year in late January 2025, including details on revenue growth across biologics, small molecules and capsules as well as updated margin indications, according to the company’s annual report released on 01/24/2025 for 2024 financials and related materials on its investor relations site Lonza investor relations as of 01/24/2025. The figures and commentary are prompting investors to revisit expectations for the coming years, especially in light of Lonza’s role as a leading contract development and manufacturing organization (CDMO) for global pharma and biotech clients, as outlined in its corporate profile and 2024 reporting Lonza annual report as of 01/24/2025.

As of: 15.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Lonza
• Sector/industry: Healthcare / contract development and manufacturing (CDMO)
• Headquarters/country: Basel, Switzerland
• Core markets: Global pharmaceutical and biotechnology customers, including the US and Europe
• Key revenue drivers: Biologics manufacturing, small molecules, cell and gene technologies, capsules and health ingredients
• Home exchange/listing venue: SIX Swiss Exchange (ticker: LONN)
• Trading currency: Swiss franc (CHF)

Lonza Group AG: core business model

Lonza Group AG’s business model is built around providing development and manufacturing services to pharmaceutical and biotechnology companies rather than marketing its own branded medicines. The group acts as a contract development and manufacturing organization, or CDMO, supporting customers from early-stage research through to commercial-scale production, according to its corporate description and latest annual report for the 2024 financial year published on 01/24/2025 Lonza annual report as of 01/24/2025.

This model typically involves long-term, multi-year contracts that can span the entire lifecycle of a drug, from clinical trial material to full-scale commercial supply. By focusing on manufacturing and development services, Lonza aims to provide its clients with flexible capacity, technology platforms and regulatory expertise, while reducing the need for pharmaceutical companies to invest heavily in their own manufacturing infrastructure, according to the company’s strategy outline in its 2024 annual reporting Lonza annual report as of 01/24/2025.

The group positions itself as a partner of choice for complex biologics, cell and gene therapies and other advanced modalities. These areas often require high technical expertise and stringent quality standards, factors that can raise the barriers to entry for smaller competitors. In addition, Lonza continues to operate in more established areas such as small molecule active pharmaceutical ingredients and drug capsules, which provide a diversified revenue base and exposure to a wide range of therapeutic areas, as described in its business segment overview in the 2024 report Lonza business overview as of 01/24/2025.

From an operational perspective, the company’s footprint includes major manufacturing sites in Europe, North America and Asia. This global network allows Lonza to serve multinational clients with region-specific needs, including access to the large US healthcare and biopharma market. Capacity utilization, project mix and ramp-up of new facilities remain key drivers for profitability, with management highlighting optimization initiatives and disciplined capital allocation as priorities in its 2024 financial commentary Lonza investor relations as of 01/24/2025.

Main revenue and product drivers for Lonza Group AG

Lonza organizes its activities into segments that include biologics, small molecules, cell and gene technologies, and capsules and health ingredients. According to the 2024 annual report released on 01/24/2025, biologics manufacturing remained a key contributor to group revenue for the 2024 financial year, reflecting demand for monoclonal antibodies and other complex biologic drugs among large pharmaceutical and biotechnology clients Lonza annual report as of 01/24/2025.

Within biologics, the company provides services ranging from cell line development to large-scale commercial production in stainless steel and single-use bioreactors. Contract structures may span multi-year supply agreements, which can offer a degree of revenue visibility but may also involve significant upfront capital investments for capacity expansion. In the 2024 reporting, Lonza emphasized continued investment in biologics facilities to support both existing and new long-term contracts, while monitoring utilization and project timing to protect margins, as outlined in its strategic and financial review for 2024 published on 01/24/2025 Lonza strategy review as of 01/24/2025.

Small molecule manufacturing remains another important driver, supporting both originator and generic pharmaceutical products. Services cover active pharmaceutical ingredients and intermediates, often for complex chemistries where regulatory and technical barriers are high. Meanwhile, the capsules and health ingredients segment supplies gelatin and vegetarian capsules as well as nutritional and functional ingredients used in over-the-counter products and supplements. According to the 2024 annual report, this business generates more diversified end-market exposure, including consumer health channels alongside prescription medicines, for the 2024 financial year as documented in the segment section released on 01/24/2025 Lonza segment information as of 01/24/2025.

In the cell and gene technologies area, Lonza is active in manufacturing viral vectors, cell therapies and related advanced treatments. Although still representing a smaller share of group revenue compared with established biologics, management has repeatedly highlighted this field as a strategic growth opportunity, given the pipeline of cell and gene therapy candidates under development with global biopharma partners. The 2024 financial reporting underlined ongoing investments in specialized facilities and platforms to support these programs for the 2024 period, while also acknowledging the inherent volatility linked to clinical trial outcomes and funding cycles among biotech customers, according to the group’s 2024 annual report published on 01/24/2025 Lonza cell and gene update as of 01/24/2025.

Why Lonza Group AG matters for US investors

For US investors, Lonza Group AG offers exposure to the global pharmaceutical and biotech supply chain through a diversified CDMO model. While the stock is primarily listed on the SIX Swiss Exchange under the ticker LONN and trades in Swiss francs, the company generates a significant portion of its business from international clients, including many groups listed in the United States, as highlighted in its geographic breakdown and customer base commentary in the 2024 annual report released on 01/24/2025 Lonza geographic information as of 01/24/2025.

Lonza’s role as a manufacturing partner for many innovative therapies means that its performance can be indirectly linked to broader trends in US drug development and funding cycles. When US biotech funding is robust and pipelines advance, demand for external development and manufacturing capacity tends to increase, potentially supporting Lonza’s order intake and capacity utilization. Conversely, periods of tightening funding or delayed product launches may weigh on project starts and can influence the timing of revenue recognition, as discussed in the risk and outlook sections of its 2024 reporting for the 2024 period, which were made available on 01/24/2025 Lonza risk discussion as of 01/24/2025.

From a portfolio perspective, Lonza shares may be considered by US investors who are interested in healthcare and life sciences infrastructure rather than direct exposure to single drug development outcomes. The CDMO model tends to diversify project risk across multiple clients and molecules. At the same time, US-based investors need to consider currency exposure to the Swiss franc, differences in regulatory environments between Switzerland and the United States, and the fact that trading primarily takes place on a foreign exchange, which may affect liquidity and access through certain brokerage platforms, as noted in Lonza’s shareholder information section in its 2024 annual report released on 01/24/2025 Lonza shareholder information as of 01/24/2025.

Conclusion

Lonza Group AG remains one of the key players in the global CDMO industry, with a business model that is tightly linked to long-term partnerships across the pharmaceutical and biotechnology value chain. The 2024 annual reporting and trading update published on 01/24/2025 for the 2024 financial year provide detailed insight into how biologics, small molecules, cell and gene technologies and capsules contribute to group performance, while also illustrating the capital intensity and complexity of scaling manufacturing platforms for innovative therapies, according to the company’s financial and strategic disclosures Lonza 2024 annual report as of 01/24/2025. For investors, the stock offers indirect exposure to global drug development trends, including those driven by US-based companies, but also carries the typical risks associated with foreign exchange movements, regulatory environments and fluctuations in demand from biotech customers. As with any equity investment, the decision whether to gain exposure to Lonza depends on individual risk tolerance, investment horizon and portfolio objectives, and should be considered in the broader context of healthcare and industrial holdings.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.